Pathogenic leucine-rich repeat kinase 2 (LRRK2) mutations are recognized as the most common cause of familial Parkinson's disease in certain populations. Recently, LRRK2 mutations were shown to be associated with a higher risk of hormonerelated cancers. However, how LRRK2 itself contributes to cancer risk remains unknown. DNA damage causes cancer, and DNA damage responses are among the most important pathways in cancer biology. To understand the role of LRRK2 in DNA damage response pathway, we induced DNA damage by applying genotoxic stress to the cells with Adriamycin. We found that DNA damage enhances LRRK2 phosphorylation at Serine 910, Serine 935 and Serine 1292. We further showed that LRRK2 phosphorylation is abolished in the absence of ATM, suggesting that LRRK2 phosphorylation requires ATM. It should also be noted that LRRK2 interacts with ATM. In contrast, overexpression or knockdown of LRRK2 does not affect ATM phosphorylation, indicating that LRRK2 is the downstream target of ATM in response to DNA damage. Moreover, we demonstrated that LRRK2 increases the expression of p53 and p21 by increasing the Mdm2 phosphorylation in response to DNA damage. Lossof-function in LRRK2 has the opposite effect to that of LRRK2. In addition, FACS analysis revealed that LRRK2 enhances cell cycle progression into S phase in response to DNA damage, a finding that was confirmed by 5-bromo-2 0 -deoxyuridine immunostaining. Taken together, our findings demonstrate that LRRK2 plays an important role in the ATM-Mdm2-p53 pathway that regulates cell proliferation in response to DNA damage.
Introduction
Mutations in the LRRK2 gene have been identified in families with autosomal dominant Parkinsonism, which is a common neurodegenerative disorder (1) (2) (3) . LRRK2 belongs to the ROCO protein family and contains several major functional domains, including a kinase domain and a GTP-binding regulatory domain (ROC-COR), whose activities are critical for transduction (4) , as well as a WD40 repeat and leucine-rich repeats (LRR) (5) . As a Serine and Threonine kinase, LRRK2 can be phosphorylated on multiple residues within its sequence through both autophosphorylation and activation by other upstream kinases (6) (7) (8) (9) . Previous studies showed the possible relationship between LRRK2 protein phosphorylation and mutant LRRK2 gene cytotoxic in Parkinson's disease (PD) pathogenesis (9) (10) (11) (12) (13) . Intriguingly, LRRK1 (14) and two other human ROCO proteins, DAPK1 and MFHAS1, have been implicated in the pathogenesis of cancer (15) . This suggests that the LRRK2 mutation itself might predispose to cancer. For example, Inzelberg et al. reported an increased incidence of non-skin cancers in patients with LRRK2 mutations (16) . Additionally, Strongosky et al. found an increased incidence of colon cancer in LRRK2 mutation carriers (17) . However, how the LRRK2 gene itself contributes to cancer risk is not clear.
DNA damage has emerged as a major culprit in cancer, with genome stability being supported by intricate machinery consisting of repair, damage tolerance and checkpoint pathways that counteract DNA damage (18) . The time-dependent accumulation of damage in cells and organs is associated with gradual functional decline (19) . In addition, DNA damage can trigger mutations that induce tumourigenesis or cell apoptosis, accelerate ageing, or both (20) . Ataxia telangiectasia mutated (ATM), a sensor of DNA damage, can mediate DNA damage responses to ionizing radiation and other agents that introduce doublestrand breaks in mammalian cells (21) . The kinase domain of ATM binds to a region surrounding Ser1981 that is contained within the previously described 'FAT' domain. Phosphorylation of this domain causes dimer dissociation and initiates cellular ATM kinase activity (22, 23) . p53, a tumour suppressor, is mutated in numerous types of tumour cells (24) . This molecule integrates numerous signals that control the cell cycle and cell death (25) . DNA damage may be sufficient to trigger a rise in p53 protein levels. The p53 protein in turn shuts down the division of stressed cells, inhibiting progress through the cell cycle (26) by contributing to the transient inhibition of DNA synthesis after DNA damage (27) . ATM can bind to p53 directly and is responsible for the phosphorylation of p53 Ser15 in response to various DNA damaging agents (28, 29) . Another ATM-related protein kinase is mTOR, which can inhibit p53 by promoting the translation of Mdm2, a negative regulator of p53 (30) . p21, a cell cycle inhibitor, inhibits the formation of the cyclin-cdk complexes required for the transition from G1 to S phase (31) . p21 expression is up-regulated by the p53 tumour suppressor gene in response to DNA-damaging agents (32) . Collectively, the ATM-Mdm2-p53 pathway plays a pivotal role in this cellular response to DNA damage.
Here, we investigate the role of LRRK2 in the response to DNA damage. We provide evidence showing that LRRK2 phosphorylation at Serine 910 (Ser910), Serine 935 (Ser935) and Serine 1292 (Ser1292) are enhanced in response to the DNA damaging reagent Adriamycin (AD). LRRK2 is a downstream effector of ATM that interacts with ATM and positively regulates theMdm2-p53 pathway to promote cell cycle progression into S phase in response to genotoxic stress.
Results
LRRK2 is phosphorylated in response to DNA damage DNA damage leads to double strand DNA breaks (DSBs) (33) . Direct phosphorylation is initiated at the DSB sites (34) . To evaluate the phosphorylation of LRRK2 in response to DNA damage, we first investigated whether endogenous LRRK2 could be phosphorylated at Ser935 upon DNA damage. We treated mouse embryonic fibroblasts (MEFs) with Adriamycin (AD), an agent that causes DNA damage by inducing single-and double-strand breaks in the DNA (35) . DMSO was applied as a control. Treating the MEFs with several doses of AD (0.5, 1 and 2 mM) and various periods of time (2, 6 and 8 h) caused a significant increase at Ser935 phosphorylation in a dose-and time-dependent manner, as demonstrated using western blot analysis (Fig. 1A , B, E and F). Under these experimental conditions, western blotting showed that p53 phosphorylation at Ser15 (mouse Ser18) and p53 protein were up-regulated in a dose-and time-dependent manner in response to 0 to 2 mM (Fig. 1A, C and D ) and 0 to 8 h AD treatment (Fig. 1E, G and H) . To further confirm the LRRK2 phosphorylation changes under the DNA damage, we detected phosphor-Ser910 and phosphor-Ser1292. We found that both Ser910 and Ser1292 have the similar trend of phosphorylation to that of Ser935 under AD treatment (Fig. 1A , B, E and F). To investigate the interaction between LRRK2 kinase activity and LRRK2 phosphorylation, we challenged the cells with a potent and selective LRRK2 kinase inhibitor LRRK2-IN-1 (36,37) for 2 h at various concentration (0.1, 1, 10 mM), followed by Adriamycin treatment for 8 h. Western blot analysis was conducted to detect the LRRK2 phosphorylation at Ser910, Ser935 and Ser1292. Dose response curves showed that LRRK2-IN-1 blocked the phosphorylation of LRRK2 at Ser910, Ser935 and Ser1292 at a higher concentration of 10 mM upon Adriamycin treatment (Supplementary Material, Fig. S1A and B), which indicated that LRRK2 phosphorylation is dependent on its kinase activity in response to DNA damage. Given that LRRK2 was predominantly expressed in the cytosol (38), we performed fractionation and detected an increase in LRRK2 phosphorylation in the cytosolic fraction of MEFs after 8 h with 1 mM Adriamycin treatment ( Fig.  1I and J). Histone deacetylase 1 (HDAC1) was used as a nuclear protein marker (39) to indicate the fractionation efficiency. Taken together, our findings demonstrate that DNA damage leads to LRRK2 phosphorylation.
ATM is required for LRRK2 phosphorylation in response to DNA damage, and LRRK2 interacts with ATM Ataxia telangiectasia mutated (ATM) is a key sensor of DNA damage. It manipulates the cell cycle after DNA damage by amplifying the DNA damage signal and transducing the signals to downstream effectors (40, 41) . The important effects of ATM in response to DNA damage led us to investigate whether ATM was necessary for LRRK2 phosphorylation upon DNA damage. MEFs derived from wild-type (WT) and ATM knockout (KO) mice were treated with AD for 2, 6 and 8 h. Western blot results showed a gradual increase in LRRK2 phosphorylation at Ser935 in WT cells after up to 8 h of AD treatment ( Fig. 2A and B) . However, there was no increase in LRRK2 phosphorylation in ATM deficient cells after up to 8 h of AD treatment ( Fig. 2A and  B) . Interestingly, we observed that the endogenous level of LRRK2 phosphorylation at Ser935 without AD treatment was much higher in the ATM KO cells than the WT cells, suggesting that LRRK2 phosphorylation in ATM deficient cells was so high that it could not be increased further in response to genotoxic stress. Our results indicate that ATM is required to enhance LRRK2 phosphorylation after DNA damage.
To further define the mechanism of ATM-dependent LRRK2 phosphorylation during the DNA damage response, we next sought to determine whether LRRK2 and ATM interact with each other. ATM, which is localized in the cell nucleus and is associated with chromatin and the nuclear matrix, is known to regulate p53 modification in response to genotoxic stress (42, 43) . However, others have shown that ATM is present in both the nucleus and the cytoplasm and that it plays a central role in the very early stages of damage detection by serving as a master controller of the cellular response to double-strand DNA breaks (DSBs) (44, 45) . In contrast, LRRK2 is a member of the leucine-rich repeat kinase family, and these proteins are largely expressed in the cytoplasm but also associated with the outer mitochondrial membrane (38) . To examine whether there is an endogenous interaction between LRRK2 and ATM, we immunoprecipitated LRRK2 or ATM using adult wild-type mouse brain tissue lysates. Immunoblotting analysis indicated that LRRK2 was present in the ATM immunoprecipitates and, vice versa, that ATM was present in the LRRK2 immunoprecipitates (Fig.   2C ). In addition to IgG, we have included positive control, i.e. MBP (46) and negative control, i.e. STAT3 (47) (a cytoplasmic protein which showed similar cellular compartmentalization to that of LRRK2 but did not bind LRRK2) for LRRK2, to define the specific interaction between LRRK2 and ATM. We found that MBP binds to LRRK2 but not ATM. In addition, STAT3 was found neither binding to LRRK2 nor ATM (Fig. 2D) . Our results demonstrated that LRRK2 interacts with ATM indeed is a specific and physiologically relevant interaction. To determine if a complex was formed between ATM and LRRK2 in cells, we overexpressed LRRK2 or/and ATM in HEK293T cells. Upon detection of overexpressed ATM and LRRK2 in HEK293T cells (Fig. 2E) , we performed immunoprecipitation of LRRK2 using an antibody against LRRK2. Western blot analysis revealed that ATM Increased levels of phosphor-LRRK2, phosphor-p53 and p53 were observed after exposure of the MEFs to AD in a dose-dependent manner. Representative blots are shown. (B) Quantification of phosphorylated LRRK2 (normalized to total LRRK2). Data are presented as the mean 6 SD. n ¼ 3. One-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001. (C) Quantification of phosphorylatd p53 and (D) total p53 (normalized to Actin). Data are presented as the mean 6 SD. n ¼ 3. One-way ANOVA. *P < 0.05. ***P < 0.001. (E) MEFs were treated with 1 mM AD for various periods of time. Western blotting was performed to analyse the levels of total LRRK2, phosphorylated LRRK2 (at Ser935, Ser910 and Ser1292), total p53 and phosphorylated p53. Increased level of phosphorylated LRRK2, phosphorylated p53 and total p53 were observed after exposure of the MEFs to AD in a time-dependent manner. Representative blots are shown. (F) Quantification of phosphorylated LRRK2 (normalized to total LRRK2). Data are presented as the mean 6 SD. n ¼ 3. One-way ANOVA. **P < 0.01, ***P < 0.001. (G) Quantification of phosphorylated p53 and (H) total p53 (normalized to Actin). Data are presented as the mean 6 SD. n ¼ 3. One-way ANOVA. ***P < 0.001. (I) Fractionation of MEFs into cytosolic and nuclear compartments after treatment with 1 mM AD for 8 h. Western blot results showed that LRRK2 phosphorylation at Ser935 occurs in the cytosol in response to genotoxic stress. Representative blots are shown.
(J) Quantification of phosphorylated LRRK2 (normalized to total LRRK2). Data are presented as the mean 6 SD. n ¼ 3. Student's t-test. ***P < 0.001. co-immunoprecipitated with LRRK2 ( Fig. 2E ) and vice versa, LRRK2 co-immunoprecipitated with ATM ( Fig. 2E ). In addition, we performed immunostaining for LRRK2 and ATM after their co-expression in HEK293T cells. This revealed that LRRK2 and ATM predominantly co-localize in the cytoplasmic region of the cell (Fig. 2F ). Our data therefore indicate that LRRK2 interacts with ATM.
LRRK2 is a downstream effector of ATM that regulates p53 and p21 expression in response to DNA damage LRRK2 is a serine/threonine kinase that can phosphorylate its downstream targets at threonine or serine residues (5). ATM was found to be phosphorylated at serine 1981 in response to DNA damage (23) . To determine whether there is reciprocal regulation that LRRK2 regulates ATM phosphorylation at Ser1981 in response to DNA damage, we knocked down LRRK2 using a LRRK2-specific siRNA in NIH/3T3 cells (Fig. 3A-F ) and overexpressed LRRK2 using MEF cells derived from transgenic LRRK2 mice (Fig. 3G-L) to investigate the effect of LRRK2 on ATM. Western blot analysis showed that ATM phosphorylation at Ser1981 gradually increased in response to DNA damage in control and WT cells (Fig. 3A and G) ; however, there was no change in ATM phosphorylation at Ser1981 in cells with either increased or decreased levels of LRRK2 compared with control and WT cells (Fig. 3A, B , G and H), indicating that LRRK2 is a downstream effector of ATM.
Interestingly, we found that two downstream effectors of ATM, p53, an essential marker for lethal DNA damage, and p21, a cell cycle inhibitor (31), were both down-regulated in the LRRK2-deficient cells (Fig. 3A, E and F) . Conversely, both p53 and p21 were up-regulated in the transgenic LRRK2-expressing cells compared with the non-transgenic WT cells in response to DNA damage (Fig. 3G, K and L) . Collectively, our findings unveiled an essential role for LRRK2 as a downstream effector of ATM that stimulates the expression of p53 and p21 in response to DNA damage.
LRRK2 regulates p53 expression by promoting the phosphorylation of Mdm2 upon DNA damage p53-mediated DNA damage induces cell cycle arrest, apoptosis, or senescence, all of which are controlled by Mdm2, the principal endogenous E3-ligase with high specificity for p53 (48) . Given that p53 was down-regulated in the absence of LRRK2 and up-regulated when LRRK2 was overexpressed (Fig. 3A , E, G and K), we next sought to determine whether Mdm2 contributes to the LRRK2-mediated regulation of p53. We knocked down LRRK2 in NIH/3T3 cells before treating the cells with AD. The Western blot results indicated that LRRK2 deficiency reduced genotoxic stress-induced Mdm2 phosphorylation at Ser166 (mouse Ser163), and p53 phosphorylation at Ser15 (mouse Ser18) relative to control cells (Fig. 3A, C and D) . In contrast, the overexpression of LRRK2 in the transgenic LRRK2-expressing cells led to the increasing of Mdm2 phosphorylation at Ser163, and p53 phosphorylation at Ser18 (Fig. 3G, I and J). Moreover, recent studies have shown that mTOR can inhibit p53 by increasing the translation of Mdm2 (49) . We further investigated whether mTOR pathway play a role in LRRK2-mediated regulation of p53. We conducted western blot detection of the p70S6K phosphor-Thr398, which is the direct downstream effector of mTORC1 activity. The results showed that p70S6K phosphorylation level was not changed in LRRK2 knockdown MEF cells (Supplementary Material, Fig. S2A and C) . In addition, we also noticed that phosphorylation of mTORC1 at 2448 showed no change (Supplementary Material, Fig. S2A and B) , suggesting LRRK2 did not affect mTOR-S6K pathway in response to DNA damage. Collectively, these results indicate that LRRK2 regulates p53 by mediating Mdm2 phosphorylation in response to DNA damage.
LRRK2 stimulates cell proliferation in response to DNA damage DNA damage elicits diverse cellular responses that are typically focused on three processes: DNA repair mechanisms, cell cycle checkpoints and apoptosis (50) . Given that our previous results showed that the cell cycle inhibitor p21 was down-regulated after DNA damage following LRRK2 knockdown and was upregulated following LRRK2 overexpression (Fig. 3A, F, G and L) , we focused our attention on the impact of LRRK2 on cell cycle progression under genotoxic stress. First, we performed fluorescence-activated cell sorting (FACS) and analysed cell cycle progression at various phases after AD treatment for 8 h in both WT and LRRK2-expressing MEFs (Fig. 4A) . Propidium iodide (PI) staining showed that the number of cells in S phase after 8 h of DNA damage was higher in LRRK2-expressing cells than WT cells (Fig. 4B, 50% increase relative to WT). To confirm the effect of LRRK2 on the regulation of cell cycle progression in response to genotoxic stress, we treated WT and LRRK2-expressing MEFs with AD for 8 h and stained the cells with 5-bromodeoxycytidine (BrdU), a cell proliferation marker that can be incorporated into the newly synthesized DNA of replicating cells as a substitute for thymidine (51) . We counted the number of BrdU-positive cells and found that LRRK2-expressing MEF cells displayed a significantly higher number of BrdU-positive cells after AD treatment for 8 h (Fig. 4C and D, 15% increase relative to WT). In contrast, LRRK2 knockdown in AD-treated NIH/3T3 cells had the opposite effect on cell proliferation. After co-transfecting GFP with control or siLRRK2, we found a significant decrease in the number of BrdU and GFP double-positive cells in the LRRK2-depleted cells compared with control cells after DNA damage ( Fig. 4E and F, 20% decrease relative to control). Hence, the results of the BrdU staining experiments were consistent with our FACS finding that cells accumulate in S phase, indicating that LRRK2 stimulates cell proliferation in response to DNA damage.
Discussion
A recent study showed that a defective DNA damage response was associated with neurodegenerative diseases (52) . Many studies have suggested that LRRK2 mutations that enhance kinase catalytic activity may contribute to PD (2, 46, 53) . LRRK2 mutations seem to be the culprit in several cellular models where the overexpression of LRRK2 leads to aggregation and cellular toxicity (54) . However, the primary physiological function of LRRK2 in DNA damage response pathway associated with cancer remains unknown. PD patients who harbour LRRK2 G2019S mutations may have increased risks of melanoma (55) (56) (57) . In a multinational study to investigate the relationship between LRRK2 G2019S mutation and cancer outcomes among PD patients demonstrates that LRRK2 G2019S mutation carriers have an overall increased risk of cancer, especially for hormonerelated cancer and breast cancer in women (58) . The investigation of the associations between LRRK2 mutations and cancer among PD patients are warranted to better understanding the underlying genetic susceptibility between PD and hormonerelated cancers. So far, LRRK2 links to cancer are only indirect and suggestive (55) (56) (57) (58) . Here, we show that LRRK2, an important molecule that regulates neurotoxicity in PD, was hyperphosphorylated during DNA damage. LRRK2 maintains genomic stability by interacting with ATM, acts as a downstream effector of ATM, enhances the phosphorylation of serine residues on Mdm2, and promotes p53 phosphorylation to enhance cell cycle progression into S phase in response to genotoxic stress (Fig. 5) .
In addition to DNA deterioration in cancer, more studies have recently suggested that DNA damage may contribute to neurodegenerative diseases. The accumulation of unrepaired DNA lesion in neurons is associated with several neurodegenerative diseases, including Alzheimer's, Huntington's and Parkinson's disease (59) . One reason for this may be a deficiency in cellular DNA repair processes during neurodegeneration (60) . Another reason is the limited capacity to replace neurons in adulthood, potentially causing the accumulation of damaged but irreplaceable cells (61) . Additionally, accelerated DNA damage may contribute to reduced gene expression, which selectively targets learning, memory and neuronal survival in the human brain (20) . A recent study suggested that oxidative DNA damage may contribute to dopaminergic neurodegeneration in the substantia nigra (SN) of patients with PD (62) . The proportion of SN neurons reactivated by 8-hydroxyguanosine (8OHG), a common product of nucleic acid oxidation, was significantly greater in PD patients compared with age-matched controls phor-Mdm2/Mdm2, phosphor-p53, p53 and p21 protein levels are shown respectively. Data are presented as the mean 6 SD. n ¼ 3. One-way ANOVA, *P < 0.05, **P < 0.01, ***P < 0.001. (G) Overexpression of LRRK2 promotes the expression of p53 and p21 in response to AD treatment. MEFs derived from transgenic LRRK2 and non-transgenic control (WT) mice were treated with 1 mM AD for different periods of time (2, 6 and 8 h). The expression of each protein was analysed by western blotting.
Representative blots are shown. (H-L) Quantification of phosphor-ATM/ATM, phosphor-Mdm2/Mdm2, phosphor-p53, p53 and p21 protein levels are shown respectively. Data are presented as the mean 6 SD. n ¼ 3. One-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001. (62) . In addition, another in vitro study showed that, under normal conditions, p53 is a substrate of LRRK2, and the phosphorylation of p53 by LRRK2 can induce p21 expression (63) , thus suggesting that LRRK2 might play a role in the response to genotoxic stress. However, the primary function of LRRK2 in the DNA damage pathway is not clear.
LRRK2 is a multi-domain protein belonging to the ROCO family of proteins that contains a kinase and GTPase domains and other protein interaction domains. Mass Spectrometric analyses (6, 53, 64, 65) had shown that LRRK2 is phosphorylated in cells at multiple amino-terminal sites to the leucine-rich repeat (LRR) domain (6-7). These sites including Ser910, Ser935, Ser955 and Ser973 (phosphorylation hot spots); however, these phosphorylation sites are not thought to be the result of autophosphorylation of the kinase. They are plausible to be activated by other kinases i.e. IkB kinases, which phosphorylates LRRK2 at Ser935 (8) . Also, phosphorylation at Ser910 and Ser935 of LRRK2 has been reported to be required for binding of 14-3-3 proteins (9), More than 300 BrdU-positive cells were counted for each condition. Data are presented as the mean 6 SD. n ¼ 3. One-way ANOVA. ***P < 0.001. (E) LRRK2 deficiency decreases cell proliferation. NIH/3T3 cells were co-transfected with siRNA targeting LRRK2 (siRNA LRRK2) and GFP for 48 h. Cells were treated with 1 mM AD for 8 h, incubated with BrdU for 2 h and immunostained for BrdU. Representative images are shown. Arrowheads indicate cells positive for both GFP and BrdU. Scale bars, 50 lm.
(F) The number of BrdU and GFP double-positive cells was counted against the total number of GFP-positive cells. More than 80 GFP-positive cells were counted for each condition. Data are presented as the mean 6 SD. n ¼3. One-way ANOVA. **P < 0.01, ***P < 0.001. and LRRK2 interacts with14-3-3 phosphor-binding adaptor isoforms is mediated by phosphorylation of Ser910 and Ser935 located prior to the leucine rich repeat domain mediates (64) . Interestingly, 14-3-3 binding has been linked to PD, as Ser910 and Ser935 interaction with the 14-3-3 is inhibited by five of the six validated LRRK2 pathogenic mutations (R1441C, R1441G, R1441H, Y1699C and I2020T) (64) . Similarly, our result demonstrated that DNA damage led to LRRK2 hyperphosphorylation at Ser910, Ser935 and Ser1292 (Fig. 1) . Notably, DNA damage sensor ATM (a Serine/threonine kinase was found to be phosphorylated at serine 1981 in response to DNA damage) (66-68) is required for LRRK2 Ser935 hyperphosphorylation (Fig. 2A) . These data suggest ATM may have a role in regulating this phosphorylation event but does not exclude the possibility that additional kinases involved in DNA damage response may induce phosphorylation of LRRK2 at this residue (69) . Cellular responses to DNA damage are mediated by a number of protein kinases, such as ATM (42) . We demonstrated that ATM deficiency impairs the phosphorylation response of LRRK2 at Ser935 after DNA damage, but the endogenous phosphorylated LRRK2 level was up-regulated under control conditions without drug treatment ( Fig. 2A) . Given the result of immunoprecipitation assay (Fig. 2C, D and E) , it is plausible that ATM can interact with LRRK2 and mask the phosphorylation sites under physiological conditions, which may prevent such sites from being hyperphosphorylated either by other kinases such as inhibitory kappa B kinases (IKKs) (8) or by autophosphorylation (70) , thereby the phosphorylation of those sites would be saturated in the absence of ATM under DNA damage. Apart from using loss-of function in ATM (knockout) to show that ATM is required for LRRK2 phosphorylation in response to DNA damage, in vitro kinase assay by mixing LRRK2 and ATM recombinant proteins followed by kinase assay and LRRK2 phosphorylation detection would be useful to demonstrate the direct link between ATM and LRRK2 phosphorylation (71) .
However, although LRRK2 knockdown had no effect on ATM phosphorylation, it did decrease p53 and p21 expression in response to genotoxic stress (Fig. 3A, E and F) , revealing that ATM may be essential for LRRK2 activation rather than vice versa. Interestingly, our results showed that p53 and p21 were significantly up-regulated by LRRK2 after 6 h of AD treatment (Fig. 3G, K and L) , whereas the phosphorylation of their upstream regulators ATM was not changed, but phosphorylation of Mdm2 was increased after 2 h of DNA damage (Fig. 3G, H and I), suggesting that LRRK2 regulates Mdm2 phosphorylation to facilitate changes in the expression of downstream targets such as p53 and p21 upon DNA damage. This is consistent with the potential mechanism that Mdm2 phosphorylation can prevent p53 polyubiquitination and lead to p53 stabilization (72) . Therefore, our finding indicates that ATM-LRRK2 signalling regulates p53 in response to DNA damage is mediated through Mdm2 phosphorylation.
Notably, we found that ATM was able to interact with LRRK2 in the cytoplasm, the primary location of LRRK2 protein (38) (Fig. 2F) , instead of LRRK2 translocating to the nucleus, where ATM is predominantly expressed, as people previously speculated (43) . ATM is predominantly present in the nucleus, yet a small fraction is also present in the cytoplasm (44) , and in some cases ATM can also translocate into cytoplasm (73, 74) . Thus, it is possible that LRRK2 can interact with ATM to form the ATM-LRRK2 complex in the cytoplasm, which may promote the activation of LRRK2 under genotoxic stress.
DNA repair is an important aspect of genomic maintenance when cells are actively proliferating (50) . In our study, quantification of BrdU-positive cells and FACS analysis both revealed that LRRK2 induces cell proliferation upon DNA damage at a certain point during AD treatment (Fig. 4) , suggesting that LRRK2 may address hazardous DNA damage by affecting the replication mechanisms in S phase. Although our findings demonstrate that LRRK2 plays a vital role in genomic maintenance during replication, there is a need to investigate whether LRRK2 can mediate genome integrity by regulating DNA repair in the future.
The activation of p53-mediated transcription is thought to be a critical cellular response to DNA damage (75) . Previous studies have implied that p53 plays a central role in chronic neurodegenerative diseases (76) . For instance, p53 levels are increased in PD (77) . Interestingly, a recent study described p53 as a LRRK2-interacting protein and found that it acts as a LRRK2 kinase substrate (62) . Their study showed that LRRK2 can phosphorylate threonine (Thr) at the p53 TXR motif, causing p53 to translocate to the nucleus. Furthermore, N-terminalpositions in p53, such as T304 and T377, which are important for p53 function, are hyperphosphorylated by LRRK2. However, the role of LRRK2 in the cellular response to DNA damage remains unknown. In our study, we used multiple approaches to demonstrate that LRRK2 is phosphorylated in response to genotoxic stress and is regulated by ATM to regulate cell proliferation in response to DNA damage. Our finding showed that DNA damage induced phosphorylation of Ser910, Ser935 and Ser1292, suggesting that the physiological Ser910/Ser935/Ser1292 kinase is regulated by LRRK2 and that LRRK2 might be activated and thus function as an upstream protein kinase that is able to transduce signaling to mediate the downstream effector of Mdm2-p53 in DNA damage pathway.
In summary, we have demonstrated that LRRK2 is phosphorylated in response to DNA damage and that LRRK2 in turn maintains genomic stability by interacting with ATM and regulating Mdm2-p53-mediated cell cycle progression at the proliferation stage. These observations suggest that LRRK2 phosphorylation may protect the cell from abnormal proliferation in response to DNA damage.
Materials and Methods

Mice
Transgenic LRRK2 mice were purchased from Jackson Laboratory (#012466). C57BL/6 mice were purchased from In Vivo Company, Singapore. Mice were maintained in accordance with the institutional guidelines, and all protocols were approved by the Institutional Animal Care and Use Committee (IACUC) of the National Neuroscience Institute, Tan Tock Seng Hospital. The mice were maintained in a pathogen-free facility and exposed to a 12 h light/dark cycle with access to food and water ad libitum. Methods involving mice were carried out in accordance with the approved guidelines.
Cell culture and transfection
Low passage (p3-p5) mouse embryonic fibroblasts (MEFs) were prepared as previously described (78 
Immunoprecipitation and western blotting
After AD treatment, cells were washed with PBS, and proteins were extracted by lysis in RIPA buffer containing phosphatase and protease inhibitors. The protein concentration was determined using a Bio-Rad assay. Equal amounts of protein were separated using 6-12% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto polyvinylidenedifluoride membranes (Millipore) for immunoblotting. Non-specific binding was blocked by incubation in 5% BSA in Tris-buffered saline containing 0.1% Tween 20 (TBS-T) for 1 h at room temperature. Next, the membranes were incubated separately with primary and secondary antibodies and visualized using an ECL kit (GE Healthcare). For immunoprecipitation, antibodies were added to the cell lysates and incubated at 4 C for 4 h followed by incubation with protein A plus G beads at 4 C for 1.5-2 h. The immunoprecipitated proteins were released from the beads by boiling for 10-min and subsequently analysed with western blotting.
FACS analysis
After AD treatment, cells were trypsinized and collected by centrifugation at 150g for 5 min. For cellular DNA content analysis, cells were washed once with PBS and subsequently fixed in prechilled 70% ethanol at -20 C overnight. The ethanol solution was then removed, and the cells were washed once with PBS containing 5 mM EDTA. The cells were then resuspended in propidium iodide (PI) (80) cocktail buffer containing boiled RNase A and EDTA and incubated for 4 h in the dark at room temperature, as described previously (81) . The number of PI-stained cells was immediately acquired using an LSRII flow cytometer (Becton Dickinson Biosciences) and analysed using WinMDI Version 2.9 software (The Scripps Research Institute, La Jolla, CA, USA).
Immunocytochemical staining
After transfection, cells were fixed with 4% paraformaldehyde Image acquisition, western blot quantification and statistical analysis
For each experiment, at least 3 independent replicates were performed, and similar results were obtained. Representative results from one experiment are shown. For quantification, all western blots were scanned with a Molecular Dynamics scanning densitometer. Statistical analysis was performed using ANOVA followed by TUKEY HSD test and Student's t test. Quantitative data were expressed as the mean 6 SD. A significant difference was defined as *P < 0.05, **P < 0.01, or***P < 0.001 compared with the control.
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